Aug 11, 2020
MagVenture receives FDA clearance for OCD
Apr 16, 2020
America's State of Mind: Use of Mental Health Medications Increasing with Spread of Coronavirus
Mar 09, 2020
The global premenstrual syndrome treatment market was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026
Feb 10, 2020
NeuroRx: Phase 3 Drug for Suicidal Bipolar Depression to Present at BIO CEO Conference
Jan 15, 2020
BayView Professional Associates introduces new option for treating major depressive disorder
Jan 13, 2020
Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression and Others): Pipeline Review, Developer Landscape and Competitive Insights, 2019
Dec 16, 2019
Advanced Treatment for Depression Without Medication
Nov 18, 2019
Pharmactive Affron® Saffron Helps Beat the Blues
Oct 15, 2019
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
Oct 03, 2019
Pacific Ketamine Institute Introduces SPRAVATO(TM) Treatment for Depression and Mental Disorders
Aug 19, 2019
Researchers at USU Unveil Neuronetics®-supported Clinical Research for PTSD and Traumatic Brain Injury at the Military Health System Research Symposium
Aug 01, 2019
Neuronetics® Announces First TMS Patient Treated Under New Japan Reimbursement Policy
Jul 29, 2019
Neuronetics® Launches TrakStar® Plus Patient Data Management System to Maximize Physician Time with Patients
Jul 23, 2019
Kalypso Wellness Center Patients See 90 Success Rates
Jul 08, 2019
NeuroStar® Patient Outcomes Registry Has Now Surpassed 3,000 Evaluable Patients, Making It The World's Largest in Major Depressive Disorder
Jun 11, 2019
Actify Neurotherapies Announces Launch of SPRAVATO(TM) Pilot Program
May 31, 2019
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
May 30, 2019
Lemonaid Health launches first on demand depression and anxiety online treatment service
May 21, 2019
New Data Highlights the Value of SPRAVATO(TM) (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]
Apr 22, 2019
Anti-depressant Prescriptions Associated with Increased Total Workers' Compensation Claims Cost, Delayed Return to Work